VivoSeq
Neurology

Rhabdomyolysis

7

Pipeline Programs↗

2

Active Trials↗

3

Companies Involved↗

Rhabdomyolysis is an early-stage landscape with 7 programs across 3 companies. The most active players are Novartis, Arbor Pharmaceuticals, Inc., Calm Water Therapeutics LLC. 3 therapies are approved.

Intelligence

Pipeline Metrics

Competitive Density

33/100

Pipeline Velocity

6/100

Mech. Concentration

50/100

Completion Rate

75/100

Attrition Rate

17/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Novartis logo

Novartis

2 programs

Phase 2A

Arbor Pharmaceuticals, Inc.

1 program

ApprovedC

Calm Water Therapeutics LLC

1 program

Approved

Pipeline

Programs by Phase

Analysis

Trial Status

6

clinical trials

Completed3 · 50%
Recruiting2 · 33%
Withdrawn1 · 17%

Clinical Trials

Trial Activity

6 trials

Dexamethasone Use in Pediatric Rhabdomyolysis Patients in Addition to Standard Protocols
Recruiting·—·Phase 1·NCT06429982·50 enrolled
The Rhabdomyolysis Evaluation in the Emergency Department (REED) Score - a Risk Prediction Model for Older Adults in the Emergency Department With Rhabdomyolysis After Prolonged Immobilisation ("Long Lie")
Recruiting·University of Salford·N/A·NCT07158554·1,000 enrolled
Study of N-Acetylcysteine (NAC) and Continuous Renal Replacement Therapy (CRRT) for the Treatment of Rhabdomyolysis
Completed·—·Phase 2·NCT00391911·3 enrolled
Lactoferrin Effect on Kidney and Heart of Rhabdomyolysis Rats
Completed·—·Phase 4·NCT06491394·24 enrolled
Plasma Neutrophil Gelatinase Associated Lipocalin Levels During Emergency Management of Rhabdomyolysis
Completed·—·N/A·NCT01544231·197 enrolled
Acute Rhabdomyolysis and Muscle Pain Associated With Mutations in the LPIN1 Gene - A Retrospective Study Describing the Safety and Efficacy of Hydroxychloroquine Sulfate Given on a Compassionate Basis to Patients Suffering From Lipin-1 Deficiency
Withdrawn·AAssistance Publique - Hôpitaux de Paris·N/A·NCT04007562

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)